Company confirms 12 patients enrolled in Phase 2 THIO-101 to date as expansion trial adds new countries Posters for Phase 2 and Phase 3 clinical trials available CHICAGO , Nov. 21, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced highlights from two poster presentations delivered at SITC 2025, an annual conference hosted by the Society for Immu ...

Core Insights - MAIA Biotechnology, Inc. has reported positive efficacy data from its Phase 2 clinical trial, THIO-101, which evaluates ateganosine (THIO) in combination with cemiplimab for advanced non-small cell lung cancer (NSCLC) patients who have failed multiple standard therapies [1][2] Group 1: Efficacy Data - The Phase 2 trial THIO-101 shows a progression-free survival (PFS) of 5.6 months, which is more than double the standard of care PFS of 2.5 months [2][6] - The estimated median overall survival (OS) is reported at 17.8 months, with a 95% confidence interval lower bound of 12.5 months [6] Group 2: Drug Mechanism and Development - Ateganosine is a first-in-class investigational telomere-targeting agent that induces telomerase-dependent telomeric DNA modification and selective cancer cell death [3] - The drug activates both innate and adaptive immune responses, leading to significant tumor regression in advanced cancer models [3] Group 3: Clinical Trial Design - THIO-101 is a multicenter, open-label, dose-finding Phase 2 clinical trial designed to evaluate ateganosine's anti-tumor activity when followed by PD-(L)1 inhibition [4] - The trial has two primary objectives: to evaluate the safety and tolerability of ateganosine and to assess its clinical efficacy using Overall Response Rate (ORR) as the primary endpoint [4] Group 4: Company Overview - MAIA Biotechnology focuses on developing targeted immunotherapies for cancer, with ateganosine being its lead program aimed at treating NSCLC patients with telomerase-positive cancer cells [7]